PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC
Q2 2026 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0001844645
· CRD 287988
· Exempt reporting adviser
Holdings reported by
Nan Fung Group Holdings Ltd since Q2 2021
Consolidated report · includes
1 manager
since Q4 2020
$307.8M Reported Value Total
Exempt Reporting Adviser
PIVOTALBIOVP.COM
Source: Form ADV filed 2026-06-25
Reported value
$307.8M
Quarter over quarter
-2.0%
Holdings
13
Top-10 concentration
95.1%
Filing Structure
Reports holdings for
- Pivotal bioVenture Partners Fund I U G P Ltd · File #028-20631 · since Q4 2020
Holdings reported by
- Nan Fung Group Holdings Ltd · since Q2 2021 · declared by one filing
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Robert Hopfner
Managing Partner
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2026 13F record
Q2 2026 13F filing summary
| Period of report | June 30, 2026 |
|---|---|
| Filed | August 13, 2026 |
| Form | 13F-HR |
| Reported value | $307.8M |
| Positions | 13 |
| Change in reported value | +10.0% |
| New positions | 1 |
| Exited positions | 1 |
| Position turnover | 14.3% |
| Top-10 concentration | 95.1% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 13, 2026
|
13 | $307.8M |
|
Q1 2026 13F
Filed May 14, 2026
|
13 | $279.8M |
|
Q4 2025 13F
Filed Feb 13, 2026
|
12 | $258.7M |
|
Q3 2025 13F
Filed Nov 13, 2025
|
10 | $173.0M |
|
Q2 2025 13F
Filed Aug 13, 2025
|
12 | $161.3M |
|
Q1 2025 13F
Filed May 14, 2025
|
11 | $123.6M |
|
Q4 2024 13F
Filed Feb 13, 2025
|
11 | $148.1M |
|
Q3 2024 13F
Filed Nov 13, 2024
|
11 | $168.5M |
|
Q2 2024 13F
Filed Aug 13, 2024
|
10 | $130.1M |
|
Q1 2024 13F
Filed May 14, 2024
|
11 | $155.6M |
|
Q4 2023 13F
Filed Feb 13, 2024
|
13 | $394.2M |
|
Q3 2023 13F
Filed Nov 13, 2023
|
13 | $250.7M |
|
Q2 2023 13F
Filed Aug 11, 2023
|
11 | $303.3M |
|
Q1 2023 13F
Filed May 12, 2023
|
11 | $242.9M |
|
Q4 2022 13F
Filed Feb 13, 2023
|
10 | $230.0M |
|
Q3 2022 13F
Filed Nov 10, 2022
|
11 | $273.7M |
|
Q2 2022 13F
Filed Aug 12, 2022
|
11 | $198.5M |
|
Q1 2022 13F
Filed May 13, 2022
|
11 | $211.4M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
10 | $239.2M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
9 | $282.9M |
3 earlier quarters on file — choose one from the quarter menu above.
Top 13 holdings · Q2 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | PCVX VAXCYTE INC | $82.9M | 26.92% |
| 2 | ARQT ARCUTIS BIOTHERAPEUTICS INC | $33.2M | 10.78% |
| 3 | TRVI TREVI THERAPEUTICS INC | $32.5M | 10.56% |
| 4 | AVLN AVALYN PHARMACEUTICALS INC | $31.8M | 10.34% |
| 5 | EVMN EVOMMUNE INC | $25.6M | 8.32% |
| 6 | MPLT MAPLIGHT THERAPEUTICS INC | $21.9M | 7.12% |
| 7 | OCS OCULIS HOLDING AG | $20.9M | 6.79% |
| 8 | BIOA BIOAGE LABS INC | $16.0M | 5.2% |
| 9 | IMNM IMMUNOME INC | $15.5M | 5.04% |
| 10 | ZBIO ZENAS BIOPHARMA INC | $12.5M | 4.05% |
| 11 | AVTX AVALO THERAPEUTICS INC | $8.0M | 2.61% |
| 12 | RLYBZZZZ RALLYBIO CORP | $4.8M | 1.56% |
| 13 | RXRX RECURSION PHARMACEUTICALS IN | $2.2M | 0.71% |
Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.